Breaks Categories: News

ThursdayOct 21, 2021 9:52 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Clinical Hold on Planned Eating Disorder Phase 2a Study

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, reported that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on its upcoming Phase 2a study for eating disorders. According to the announcement, the FDA did not cite a reason for the hold but would provide additional information regarding the hold in the next month. Although the study is now on hold, the company noted that it still expects to move forward with plans to file an IND for its Phase 2a study in fibromyalgia; that…

Continue Reading

TuesdayOct 19, 2021 10:50 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Founder of Synergy Soul to Headline at Meet Delic

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Brittany Hoogenboom will serve as a keynote speaker at Meet Delic on Nov. 7, 2021. Hoogenboom is the owner and founder of Synergy Soul, a brand focused on personal transformation through a holistic, integrated approach to life, business and wealth. She is also a certified physical therapy assistant, reiki master and yoga instructor. “We are very excited to have Brittany’s fresh voice and approach to personal transformation at Meet Delic,” said Delic co-founder, Jackee Stang. “She has a unique way of integrating health, wellness, spirituality and…

Continue Reading

TuesdayOct 19, 2021 10:12 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin’s research and development team has completed 74 in-vitro and in-vivo evaluations of the company’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions. More than 50 novel compounds have been evaluated to date through collaborations with experienced contract research organizations for pharmacokinetic/pharmacodynamic profile, metabolic stability, receptor binding and safety to…

Continue Reading

FridayOct 15, 2021 10:39 am

PsychedelicNewsBreaks – IBN and PsychedelicNewsWire to Heighten Visibility, Widen Reach of Upcoming Psychedelic Capital Conference

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, today announced that it will collaborate with Microdose Psychedelic Insights, a cutting-edge media company aiming to move the psychedelics industry to the forefront of modern medicine, for its upcoming event. The Psychedelic Capital Conference, set to be held in an entirely virtual format on Oct. 28, 2021, will feature the most innovative and cutting-edge companies, latest IPOs, newest opportunities and deepest insights into the global psychedelic industry. The event will serve to educate attendees on the potential uses and benefits attached to psychedelics in today’s environment, from exploring ongoing governmental policy…

Continue Reading

ThursdayOct 14, 2021 3:22 pm

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Announces Strategic Board Appointments of Distinguished Addiction Experts

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that professors Wim van den Brink and Gabriele Fischer have joined the company’s scientific advisory board. According to the update, van den Brink, M.D., Ph.D., is a professor of addiction psychiatry at the Academic Medical Center of the University of Amsterdam and a recognized expert in the neurobiology and pharmacological treatment of substance use disorders and behavioral addictions. Gabriele Fischer, M.D., is a professor of addiction research and treatment, medical…

Continue Reading

ThursdayOct 14, 2021 12:47 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Included in AdvisorShares Psychedelics ETF

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced its inclusion in the AdvisorShares Psychedelics ETF (the “Fund”), currently trading under ticker symbol PSIL on the NYSE Arca exchange. According to the update, the Fund, launched in September 2021, is actively trading and focuses on companies that devote a majority of assets to psychedelic drug development. The Fund has built a portfolio including over 25 psychedelic companies. PSIL represents an exciting milestone for Tryp with the potential to bring a more diverse shareholder base and to broaden life science exposure for…

Continue Reading

ThursdayOct 14, 2021 9:58 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Collaboration to Provide Veterans with Free Ketamine Treatments

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced two new partnerships between Ketamine Wellness Centers LLC (“KWC”) and the Veterans Administration (“VA”) Community Care Networks of Illinois and Minnesota . According to the update, the nation’s largest chain of psychedelic wellness clinics, KWC, will offer ketamine treatments to veterans at no out-of-pocket cost at their locations in Naperville, Illinois, and Burnsville, Minnesota. The program is designed to cover patients experiencing post-traumatic stress disorder (“PTSD”), major depression and chronic pain who have exhausted all traditional medical treatments. “This partnership between KWC and the VA…

Continue Reading

TuesdayOct 12, 2021 11:59 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Duncan Trussell to Keynote at Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that Duncan Trussell will serve as a keynote speaker at Meet Delic on Nov. 6, 2021. An actor and stand-up comedian, Trussell co-created and appears in the Netflix animated series “The Midnight Gospel” and regularly travels the country performing comedy at festivals and shows. He also hosts the “Duncan Trussell Family Hour” podcast. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, wellness and business with like-minded visionaries. Trussell's keynote will be a live taping of his podcast,…

Continue Reading

TuesdayOct 12, 2021 11:28 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the KCSA Psychedelics Virtual Investor Conference at 3:00 p.m. ET on Oct. 14, 2021. The event is slated to take place virtually on Oct. 13-14, 2021. Tryp’s Chief Financial Officer Luke Hayes will provide a live overview of the company's activities and elaborate on how Tryp is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. Interested parties should visit https://ibn.fm/1Y2RX to…

Continue Reading

TuesdayOct 12, 2021 10:48 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. According to the update, the application, governed by the Patent Cooperation Treaty (“PCT”), brings the potential to obtain patent coverage in 153 countries. “The continued progression of our research programs guides our discovery of new molecules and differentiating treatment approaches,” said Doug Drysdale, the company’s CEO. “Continued innovation, as demonstrated by our expanding IP portfolio, positions Cybin as a leading…

Continue Reading